by David Porter, MD
In this month's president's message, Dr. David Porter shares highlights from the recent two-day Leadership Course in Washington, D.C., celebrating the connections between rising and...
by Blood
Researchers say analogous IL-17 and CSF-1 dysregulation signatures may help optimize the use of newly approved agents for the prevention and treatment of chronic graft-versus-host disease (cGVHD),...
by ASTCT Talks
Welcome to the fourth episode of ASTCT Talks’ exclusive 8-part series, supported by an educational grant from Sanofi US. In this episode, former ASTCT President Dr. Corey Cutler sits down...
by Blood
Rovadicitinib demonstrates therapeutic potential for patients whose chronic graft-versus-host disease (cGVHD) is glucocorticoid-refractory or -dependent, researchers report.
by Alex Kadhim
In a multicenter retrospective study published in Blood Advances, authors from multiple institutions examined the impact of prior inotuzumab ozogamicin (InO) exposure on the outcomes of...
by Alex Kadhim
Researchers from University Hospital Ostrava and the Faculty of Medicine at the University of Ostrava, Czech Republic, conducted a comprehensive review on how intrinsic T cell characteristics...